Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Variation in Quality an Important Issue for Future Biosimilars: Seminar
July 25, 2011
- Speakers at CPhI Japan 2011 Agree on Prospects for Growth in Vaccine Market
July 25, 2011
- 12 APIs Including Lixiana Added to NHI Price List
July 25, 2011
- PFSB Taking Public Comments on Revision of GLs for Equivalence Testing of Generic Drugs
July 25, 2011
- Pharmacy, Drugstore Industries Intensifying Efforts to Ensure Compliance with Regulations
July 25, 2011
- Korosho to Improve List of Accredited Foreign Drug Manufacturers
July 25, 2011
- Generics Account for 23.5% of Total Number of Drugs in 2010: Korosho Survey
July 25, 2011
- Psychiatric Disease to Be Added to 4 Designated Diseases in Healthcare Planning System
July 25, 2011
- Infrastructure Needed to Promote Orphan Drug Development: Health Minister Hosokawa
July 25, 2011
- Rate of Generic Drug Use Declined in February, March: Survey
July 25, 2011
- Korosho to Promote Anti-HTLV-1 Measures
July 25, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
- Korosho to Announce Stance on Copayments for OTC-like Drugs by Year-end
July 18, 2011
- Takeda Obtains Approval for Liovel Combination Tab
July 18, 2011
- Korosho Panel Fails to Form Consensus on HbA1c Data Reporting
July 18, 2011
- Onbrez Approved for COPD: Novartis
July 18, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…